title: Human biodistribution and dosimetry of ¹¹C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain.
abstract: As a reported agonist, ¹¹C-CUMI-101 is believed to selectively bind the G-protein-coupled state of the serotonin-1A (5-HT(1A)) receptor, thereby providing a measure of the active subset of all 5-HT(1A) receptors in brain. Although ¹¹C-CUMI-101 has been successfully used to quantify 5-HT(1A) receptors in human and monkey brain, its radiation exposure has not previously been reported. The purpose of this study was to calculate the radiation exposure to organs of the body based on serial whole-body imaging with positron emission tomography (PET) in human subjects.
  
  
  METHODS
  Nine healthy volunteers were injected with 428±84 MBq (mean ± SD) (11)C-CUMI-101 and then imaged with a PET-only device for two hours from head to mid-thigh. Eleven source organs (brain, heart, liver, pancreas, stomach, spleen, lungs, kidneys, lumbar spine L1-5, thyroid, and urinary bladder) were identified on whole body images and used to calculate radiation doses using the software program OLINDA/EXM 1.1. To confirm that we had correctly identified the pancreas, a tenth subject was imaged on a PET/CT device.
  
  
  RESULTS
  Brain had high uptake (∼11% of injected activity (IA)) at 10 min. Although liver had the highest uptake (∼35% IA at 120 min), excretion of this activity was not visible in gall bladder or intestine during the scanning session. Organs which received the highest doses (microSv/MBq) were pancreas (32.0), liver (18.4), and spleen (14.5). The effective dose of ¹¹C-CUMI-101 was 5.3±0.5 microSv/MBq.
  
  
  CONCLUSIONS
  The peak brain uptake (∼11% IA) of ¹¹C-CUMI-101 is the highest among more than twenty ¹¹C-labeled ligands reported in the literature and provides good counting statistics from relatively low injected activities. Similar to that of other ¹¹C-labeled ligands for brain imaging, the effective dose of ¹¹C-CUMI-101 is 5.3±0.5 microSv/MBq, a value that can now be used to estimate the radiation risks in future research studies.
authors: Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland, United States of America.
authors: Christina S
authors: CS
authors: Hines
authors: Jeih-San
authors: JS
authors: Liow
authors: Paolo
authors: P
authors: Zanotti-Fregonara
authors: Jussi
authors: J
authors: Hirvonen
authors: Cheryl
authors: C
authors: Morse
authors: Victor W
authors: VW
authors: Pike
authors: Robert B
authors: RB
authors: Innis
mesh_terms: D000328:Adult; D001921:Brain / Q000378:metabolism*; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D013154:Spleen / Q000378:metabolism; D014227:Triazines / Q000009:adverse effects / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: C529131:2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5-(2H,4H)-dione; D010879:Piperazines; D014227:Triazines; D044282:Receptor, Serotonin, 5-HT1A